Your browser is no longer supported. Please, upgrade your browser.
Inhibikase Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.55 Insider Own52.40% Shs Outstand10.05M Perf Week13.23%
Market Cap62.00M Forward P/E- EPS next Y-0.78 Insider Trans0.00% Shs Float4.79M Perf Month11.53%
Income-4.90M PEG- EPS next Q- Inst Own16.50% Short Float1.30% Perf Quarter-6.50%
Sales1.80M P/S34.44 EPS this Y43.30% Inst Trans1.72% Short Ratio1.91 Perf Half Y-
Book/sh0.80 P/B7.44 EPS next Y- ROA-69.30% Target Price- Perf Year-
Cash/sh0.92 P/C6.46 EPS next 5Y- ROE-251.10% 52W Range4.28 - 11.80 Perf YTD-13.68%
Dividend- P/FCF- EPS past 5Y- ROI-27.90% 52W High-49.53% Beta-
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low39.16% ATR0.44
Employees3 Current Ratio3.30 Sales Q/Q366.70% Oper. Margin- RSI (14)58.98 Volatility8.69% 8.99%
OptionableNo Debt/Eq0.15 EPS Q/Q-348.40% Profit Margin- Rel Volume2.58 Prev Close6.16
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume32.57K Price5.96
Recom- SMA2015.20% SMA5011.02% SMA200-4.62% Volume83,900 Change-3.31%
May-25-21 08:00AM  
May-17-21 04:05PM  
Apr-21-21 08:00AM  
Apr-01-21 08:00AM  
Mar-02-21 08:05AM  
Feb-22-21 08:05AM  
Feb-17-21 12:48PM  
Jan-04-21 08:01AM  
Dec-28-20 10:33AM  
Dec-23-20 05:12PM  
Dec-22-20 06:25PM  
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It is also developing IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Werner Milton H.President and CEOMay 14Option Exercise0.3843,70716,6095,288,645May 18 05:46 PM